tommaso-lizzul-shutterstock-com
tommaso lizzul / Shutterstock.com
18 February 2016EuropeCatherine Coombes

Muddied waters: the CRISPR IP landscape in Europe

The continuing interference proceedings in the US concerning clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 systems for gene-editing of eukaryotes have received much media attention. Coverage focuses on two groups: one led by Feng Zhang of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, and the other by Jennifer Doudna of the University of California, Berkeley and Emmanuelle Charpentier of the Helmholtz Centre for Infection Research. The commentary focuses on a potential winner-takes-all scenario.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
21 April 2026   With the start of the first-ever INTA Annual Meeting held in the UK capital just weeks away, in-house IP counsel share their favourite ways to spend downtime in the city.
Europe
13 April 2026   New report finds that just 13% of IP-owning firms have sought financing through their assets, with billions in potential funding left untapped, as structural barriers persist.
Europe
13 April 2026   Europe’s latest patent fee increases are modest at the EPO but include a rare steep hike in the UK, forcing applicants to reassess filing routes, portfolio value, and long-term cost strategies, say James Bell and Yelena Morozova.